FILING ANALYSIS · THURSDAY, NOVEMBER 5
C4 Therapeutics, Inc. CCCC — 8-K: Results of Operations and Financial Condition
neutral
C4 Therapeutics reported its Q3 2026 financial results and business highlights, including progress in its clinical trials for cemsidomide, but did not provide any significant quantified surprises or updates that would likely move the stock price beyond 1.5% in a week.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →